Genetic dysregulation of EP300 in cancers in light of cancer epigenome control – perspectives of specific targeting of p300 proficient and deficient cancers DOI Creative Commons
Karolina Gronkowska, Agnieszka Robaszkiewicz

Deleted Journal, Journal Year: 2024, Volume and Issue: 32(4), P. 200871 - 200871

Published: Sept. 2, 2024

Some cancer types including bladder, cervical, and uterine cancers are characterized by frequent mutations in EP300 that encode histone acetyltransferase p300. This enzyme can act both as a tumor suppressor oncogene. In this review, we describe the role of p300 initiation progression regarding aberrations have been identified TGCA Pan-Cancer Atlas studies also discuss possible anticancer strategies target mutated cancers. Copy number alterations, truncating mutations, abnormal transcriptions affect abundance activity associated with several pathological features such grading, metastases, patient survival. Elevated correlates higher mRNA level other epigenetic factors chromatin remodeling enzymes co-operate creating permissive conditions for malignant transformation, growth metastases. The status expression be considered prognostic marker immunotherapy efficacy, followed an increased PDL-1.HAT activators CTB or YF2 applied p300-deficient patients, whereas natural synthetic inhibitors activity, well dual HAT/bromodomain PROTAC degradation p300, may serve fight against p300-fueled cancers.Graphical abstract

Language: Английский

Precision Oncology, Signaling Pathways Reprogramming and Targeted Therapy: A Holistic Approach to Molecular Cancer Therapeutics DOI Creative Commons
Manish Kumar

Published: Jan. 8, 2025

Cancer is a fatal genetic disease involving unregulated cell growth and proliferation with varying underlying complexities including immune evasion, treatment resistance recurrence, optimized required for proper cure. Molecular studies have revealed that tumors are extremely heterogeneous in nature, leading to the complexity of cancer development, which ultimately linked its machinery. It would require effective targeting dysregulated molecular mechanisms factors, regulatory proteins, adhesion molecules, molecules system mainly driven by alterations tumor suppressor genes oncogenes may vary among different types. Importantly, patients same type respond differently available treatments, indicating need patient-specific options. Thus, in-depth genomic patients’ needed fully understand determinants initiation progression targeted therapy. Precision oncology has evolved as form therapy focused on profiling identify involved manifestation tailored individualized disease. Accordingly, there been great developments formulation production anticancer agents recent years owing advances technologies enabling precise oncogenic pathways progression. This article aims briefly explain foundations frontiers precision context advancements tools techniques associated process assess scope importance realizing intended goals.

Language: Английский

Citations

1
Molecular Insights on Signaling Cascades in Breast Cancer: A Comprehensive Review DOI Open Access
Venketesh K. Panda,

Barnalee Mishra,

Samikshya Mahapatra

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(2), P. 234 - 234

Published: Jan. 13, 2025

The complex signaling network within the breast tumor microenvironment is crucial for its growth, metastasis, angiogenesis, therapy escape, stem cell maintenance, and immunomodulation. An array of secretory factors their receptors activate downstream cascades regulating cancer progression metastasis. Among various pathways, EGFR, ER, Notch, Hedgehog pathways have recently been identified as in terms proliferation, survival, differentiation, maintenance CSCs, failure. These mediate such MAPK, including MEK/ERK that promote common pro-oncogenic signaling, whereas dysregulation PI3K/Akt, Wnt/β-catenin, JAK/STAT activates key oncogenic events drug resistance, CSC enrichment, metabolic reprogramming. Additionally, these orchestrate an intricate interplay between stromal cells, immune cells. Metabolic reprogramming adaptations contribute to aggressive are unresponsive therapy. Herein, recent insights into novel operating TME aid advancement emphasized current developments practices targeting enhance treatment efficacy reviewed.

Language: Английский

Citations

1
Emerging biomarkers and molecular targets for precision medicine in cervical cancer DOI

Pankaj Garg,

Madhu Krishna,

Ayalur Raghu Subbalakshmi

et al.

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2024, Volume and Issue: 1879(3), P. 189106 - 189106

Published: May 1, 2024

Language: Английский

Citations

7
Precision Oncology, Signaling Pathways Reprogramming and Targeted Therapy: A Holistic Approach to Molecular Cancer Therapeutic DOI
Manish Kumar

Authorea (Authorea), Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 9, 2025

Cancer is a fatal genetic disease involving unregulated cell growth and proliferation with varying underlying complexities including immune evasion, treatment resistance recurrence, optimized required for proper cure.Molecular studies have revealed that tumors are extremely heterogeneous in nature, leading to the complexity of cancer development, which ultimately linked its machinery.It would require effective targeting dysregulated molecular mechanisms factors, regulatory proteins, adhesion molecules, molecules system mainly driven by alterations tumor suppressor genes oncogenes may vary among different types.Importantly, patients same type respond differently available treatments, indicating need patient-specific options.Thus, in-depth genomic patients' needed fully understand determinants initiation progression targeted therapy.Precision oncology has evolved as form therapy focused on profiling identify involved manifestation tailored individualized disease.Accordingly, there been great developments formulation production anticancer agents recent years owing advances technologies enabling precise oncogenic pathways progression.This article aims briefly explain foundations frontiers precision context advancements tools techniques associated process assess scope importance realizing intended goals.

Language: Английский

Citations

0
Unraveling the kinase code: Role of protein kinase in lung cancer pathogenesis and therapeutic strategies DOI

Mena Fatma,

Sana Parveen, Snober S. Mir

et al.

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2025, Volume and Issue: unknown, P. 189309 - 189309

Published: March 1, 2025

Language: Английский

Citations

0
A Review on Integrating Breast Cancer Clinical Data: A Unified Platform Perspective DOI
Ram Mohan Ram Kumar, Suresh Joghee

Current Treatment Options in Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 3, 2025

Language: Английский

Citations

0
Precision medicine in colorectal cancer: genomics profiling and targeted treatment DOI Creative Commons
Adi Muradi Muhar, Adrian Joshua Velaro,

Arya Tjipta Prananda

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 27, 2025

Precision medicine has revolutionized the treatment of colorectal cancer by enabling a personalized approach tailored to each patient's unique genetic characteristics. Genomic profiling allows for identification specific mutations in genes such as KRAS, BRAF, and PIK3CA, which play crucial role cell signaling pathways that regulate proliferation, apoptosis, differentiation. This information enables doctors select targeted therapies inhibit molecular pathways, maximizing effectiveness minimizing side effects. also facilitates adaptive monitoring tumor progression, allowing adjustments therapy maintain effectiveness. While challenges high costs, limited access genomic technology, need more representative data diverse populations remain, collaboration between researchers, medical practitioners, policymakers, pharmaceutical industry is ensure precision becomes standard care accessible all. With continued advances support, potential improve outcomes, reduce morbidity mortality rates, enhance quality life patients worldwide.

Language: Английский

Citations

0
The current landscape of aromatase inhibitors for the treatment of estrogen receptor-positive breast carcinoma DOI

Khushboo Bhutani,

S. K. Vishwakarma,

Priyanka Yadav

et al.

The Journal of Steroid Biochemistry and Molecular Biology, Journal Year: 2025, Volume and Issue: 250, P. 106729 - 106729

Published: March 7, 2025

Language: Английский

Citations

0
The Elephant Evolved p53 Isoforms that Escape MDM2-Mediated Repression and Cancer DOI Creative Commons
Monikaben Padariya,

Mia-Lyn Jooste,

Ted R. Hupp

et al.

Molecular Biology and Evolution, Journal Year: 2022, Volume and Issue: 39(7)

Published: July 1, 2022

Abstract The p53 tumor suppressor is a transcription factor with roles in cell development, apoptosis, oncogenesis, aging, and homeostasis response to stresses infections. tightly regulated by the MDM2 E3 ubiquitin ligase. p53–MDM2 pathway has coevolved, remaining largely conserved, whereas TP53 gene morphed into various isoforms. Studies on prevertebrate ancestral homologs revealed transition from an environmentally induced mechanism activating system involving signaling. evolution of this depends structural changes interacting protein motifs. Elephants such as Loxodonta africana constitute ideal models investigate coevolution they are large long-living well having 20 copies isoformic sequences expressing variety BOX-I MDM2-binding Collectively, these isoforms would enhance sensitivity cellular stresses, DNA damage, presumably accounting for strong cancer defenses other adaptations favoring healthy aging. Here we molecular combining silico modeling vitro assays explore functional aspects retaining interaction, forming distinct pools methodology used demonstrates, first time that docking simulations can be elephant Our observations elucidate mechanistic regulation, facilitate understanding complex signaling, suggest testable hypotheses referencing Peto’s Paradox.

Language: Английский

Citations

17
Potential role of Marine Bioactive Compounds in cancer signaling pathways: A review DOI
Suryaa Manoharan, Ekambaram Perumal

European Journal of Pharmacology, Journal Year: 2022, Volume and Issue: 936, P. 175330 - 175330

Published: Oct. 17, 2022

Language: Английский

Citations

14